| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Metastatic / recurrent breast cancer remains a highly lethal disease, and it is very important to evaluate the biomarkers associated with the distant metastasis. A great majority of metastatic / recurrent breast carcinomas expresses estrogen receptor (ER), suggesting importance of estrogeic actions. However, the molecular features have remained largely unclear in the metastatic / recurrent breast carcinomas. Results our present study have demonstrated that expression profiles of microRNA and genes in the breast carcinoma were different according to the metastatic or recurrent status. Especially, miR-1, GATA4, thymidylate synthase and TACC2 played important roles in the metastasis and/or recurerence in the breast carcinoma, and they were demonstrated as potent prognostic factors of breast cancer patients. Therefore, these factors may become important therapeutic targets to improve the clinical outcome of metastatic / recurrent breast cancer patients in future.
|
